olivLaw · US equity research
OneMedNet Corporation ONMD
Services-Commercial Physical & Biological Research · SIC 8731 · Vertical: Services-Commercial Physical & Biological Research (SIC 8731)
OneMedNet Corporation provides solutions that unlock the value of clinical image archives held by healthcare providers, offering life science companies imaging real world data that is curated and meets regulatory requirements. The company still has very small revenue and recurring losses, and its network of 2,130 healthcare sites and revenue of 1.4 million USD in 2025 show the model is at an early stage.
At the close of 04 Nov 2026, OneMedNet Corporation (ONMD) stock was 4.54 USD (+7.84% on the day), with market capitalisation 269.2 m USD, beta 0.84, 52-week range 3.93–19.50 USD. Latest reported quarter (Q2 2026): revenue of 292.0 k USD (+88.4% YoY), net income of -2.2 m USD (−172.8% YoY), diluted EPS -0.04 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 45.1
- neutral
- Bollinger (20, 2)
- 3.96 – 4.99
- in the upper half of the band · %B 0.56 · band width 23.0%
- SMA 50 / 200
- 5.46 / 7.14
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.31 / -0.36
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −11.2% | −1.1% | −10.1 pp | — |
| 3 months | −29.7% | −0.5% | −29.3 pp | — |
| 6 months | −52.8% | +4.4% | −57.1 pp | — |
| Year to date | −58.7% | +12.3% | −71.0 pp | — |
| 1 year | −74.4% | +13.5% | −87.9 pp | +14.7% |
| 3 years | −92.1% | +76.4% | −168.5 pp | +18.0% |
| 5 years | −95.5% | +63.7% | −159.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 142.0 k | 26.0 k | 137.0 k | 155.0 k | 177.0 k | 891.0 k | 96.0 k | 292.0 k |
| Cost of revenue | 226.0 k | 52.0 k | 361.0 k | 396.0 k | 399.0 k | 726.0 k | 476.0 k | 857.0 k |
| Gross profit | -84.0 k | -26.0 k | -224.0 k | -241.0 k | -222.0 k | 165.0 k | -380.0 k | -565.0 k |
| Research & development | 298.0 k | 340.0 k | 348.0 k | 382.0 k | 323.0 k | 443.0 k | 311.0 k | 324.0 k |
| Operating income | -2.3 m | -2.7 m | -2.2 m | -2.1 m | -2.2 m | -3.1 m | -2.6 m | -2.3 m |
| Depreciation & amortisation | 10.0 k ≈ | 26.0 k | 12.0 k | 34.0 k ≈ | 10.0 k ≈ | 9.0 k | 11.0 k | 5.0 k ≈ |
| Interest expense | 14.0 k | 92.0 k | 31.0 k | 22.0 k | 6.0 k | 8.0 k | 10.0 k | 9.0 k |
| Net income | -2.1 m | -2.4 m | -1.9 m | 3.0 m | -741.0 k | -3.1 m | -2.5 m | -2.2 m |
| Diluted EPS | -0.07 | -0.07 ≈ | -0.06 | 0.07 | -0.01 | -0.06 ≈ | -0.04 | -0.04 |
| Operating cash flow | -1.9 m ≈ | -2.0 m | -1.9 m | -2.2 m ≈ | -1.7 m ≈ | -1.7 m | -1.5 m | -1.9 m ≈ |
| Capex | 9.0 k ≈ | 35.0 k | 5.0 k | 3.0 k ≈ | 0 ≈ | 5.0 k | 2.0 k | 9.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 1.2 m | 1.0 m | 643.0 k | 1.4 m |
| Revenue YoY | unavailable | −11.4% | −37.0% | +111.4% |
| Net income | -30.5 m | -33.8 m | -10.1 m | -2.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -7.66 | -4.65 | -0.36 | -0.06 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable |
| net % | -2,641.0% | -3,308.5% | -1,575.3% | -206.1% |
| Free cash flow | -4.8 m | -4.8 m | -7.0 m | -7.5 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 585.0 k USD
- Financial debt
- 1.2 m USD
- Net debt
- 609.0 k USD
- Equity
- -3.0 m USD
- Total assets
- 2.2 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.43x
- ROE
- unavailable
- ROA
- -95.3%
- FCF margin
- -553.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 1.2 m | 1.0 m | 643.0 k | 1.4 m | SEC (XBRL)· 30 Mar 2026verified |
| Cost of revenue | 1.5 m | 1.2 m | 924.0 k | 1.9 m | SEC (XBRL)· 30 Mar 2026verified |
| Gross profit | -360.0 k | -129.0 k | -281.0 k | -503.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Research & development | 1.6 m | 2.1 m | 1.5 m | 1.5 m | SEC (XBRL)· 30 Mar 2026verified |
| Operating income | -7.7 m | -6.9 m | -9.6 m | -9.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Depreciation & amortisation | 25.0 k | 28.0 k | 57.0 k | 65.0 k | SEC (XBRL)· 30 Mar 2026verified |
| EBITDA | -7.7 m ≈ | -6.8 m ≈ | -9.5 m ≈ | -9.6 m ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Interest expense | 403.3 k | 11.0 k | 147.0 k | 67.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Pre-tax income | -30.4 m | -33.8 m | -10.1 m | -2.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Income tax | 17.0 k | 18.0 k | 2.0 k | 1.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Net income | -30.5 m | -33.8 m | -10.1 m | -2.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Diluted EPS | -7.66 | -4.65 | -0.36 | -0.06 | SEC (XBRL)· 30 Mar 2026verified |
| Weighted average diluted shares | 4.0 m | 7.3 m | 28.1 m | 44.5 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 271.0 k | 47.0 k | 172.0 k | 585.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Receivables | 19.0 k | 152.0 k | 213.0 k | 495.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Current assets | 391.0 k | 365.0 k | 3.6 m | 2.1 m | SEC (XBRL)· 30 Mar 2026verified |
| Property, plant & equipment, net | 83.0 k | 99.0 k | 108.0 k | 56.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Total assets | 1.3 m | 464.0 k | 3.7 m | 2.2 m | SEC (XBRL)· 30 Mar 2026verified |
| Accounts payable | 1.2 m | 4.7 m | 6.0 m | 3.5 m | SEC (XBRL)· 30 Mar 2026verified |
| Short-term debt | — | 465.0 k | 9.4 m | 974.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Long-term debt | — | 465.0 k | 2.3 m | 220.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Current liabilities | 26.1 m | 13.8 m | 19.2 m | 4.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Total liabilities | 27.6 m | 13.9 m | 19.7 m | 5.1 m | SEC (XBRL)· 30 Mar 2026verified |
| Equity | -26.4 m † | -13.4 m † | -16.0 m † | -3.0 m † | SEC (XBRL)· 30 Mar 2026verified |
| Shares outstanding at year end | — | 32.3 m | 28.0 m | — | SEC (XBRL)· 17 Dec 2024verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | -4.7 m | -4.8 m | -7.0 m | -7.5 m | SEC (XBRL)· 30 Mar 2026verified |
| Capex | 58.0 k | 44.0 k | 51.0 k | 13.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Free cash flow | -4.8 m ≈ | -4.8 m ≈ | -7.0 m ≈ | -7.5 m ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Investing cash flow | -58.0 k | -44.0 k | -2.0 m | 2.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Financing cash flow | 4.3 m | 4.6 m | 9.1 m | 5.6 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 269.2 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -584.2% | 18 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 5.6% | 47 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -307.0x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 0.3x | 0 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -2.6% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 2/3 factors with a value
- Growth· partial47/100 · 1/2 factors with a value
- Quality· partial18/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ONEMEDNET CORPORATION (ONMD). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 1.4 m USD in 2025; YoY growth 111.4%; net margin -584.2%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -584.2%
- Interest coverage: -307.0x
- Current ratio: 0.3x
- FCF yield: -2.6%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Commercial Physical & Biological Research (SIC 8731) · same industry (4-digit SIC) · compared with 11 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IQVIqvia Holdings Inc. | 43.5 bn | 32.0 | 21.7% | 8.1% | +5.9% | +15% / +23% |
| INCYIncyte Corporation | 25.0 bn | 65.2 | 7.8% | 6.7% | +21.2% | +18% / +126% |
| MEDPMedpace Holdings, Inc. | 18.4 bn | 36.4 | 117.9% | 18.2% | +20.0% | +11% / +143% |
| CRLCharles River Laboratories International, Inc. | 15.6 bn | 385.5 | 1.2% | 1.0% | −0.9% | +83% / +66% |
| ICLRICON plc | 15.6 bn | 70.0 | 2.5% | 2.8% | +0.8% | +10% / −24% |
| ABSIAbsci Corp | 1.8 bn | — | -57.7% | -7,756.4% | −38.2% | +231% / +528% |
| OABIOmniab, Inc. | 755.6 m | — | -16.5% | -108.1% | −29.3% | +186% / +18% |
| NRCNRC Health | 574.5 m | 95.9 | 248.1% | 4.5% | −4.0% | +59% / −35% |
| ONMDOnemednet Corporation | 269.2 m | — | — | -584.2% | +111.4% | −74% / −92% |
| MXCTMaxCyte, Inc. | 143.5 m | — | -20.4% | -114.8% | −14.5% | −21% / −71% |
| BIAFbioAffinity Technologies, Inc. | 23.7 m | — | -1,860.2% | -257.3% | −34.2% | −87% / −100% |
| ISPCiSpecimen Inc. | 2.1 m | — | -968.5% | -2,449.0% | −79.2% | −95% / −100% |
1- and 3-year price returns: for ONMD from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
OneMedNet Corporation provides solutions that unlock the value of clinical image archives held by healthcare providers, offering life science companies imaging real world data that is curated and meets regulatory requirements. The company still has very small revenue and recurring losses, and its network of 2,130 healthcare sites and revenue of 1.4 million USD in 2025 show the model is at an early stage 1.
SWOT
Strengths
- An extensive federated network of healthcare providers built over more than a decade, giving access to clinical data that is hard to replicate. The company says it has shown the commercial and regulatory viability of imaging real world data 1.
- An in-house clinical team that curates data to each protocol's specifications, a capability that may reduce the risk of rejection by regulators 1.
- Growth in iRWD revenue in 2025 and a history of solving a real image-sharing problem point to a commercial direction that could be strengthened 1.
Weaknesses
- Net losses in every year since inception, a very large accumulated deficit relative to revenue, and a going concern warning 1.
- Revenue is very small relative to operating expenses, and gross margin is negative, showing the model does not yet cover curation and hosting costs 1.
- Dependence on equity and debt financing, with dilution risk for shareholders, and the need to cure the listing bid price condition 12.
Opportunities
- If regulators accept evidence based on clinical practice data more often, demand for curated imaging data could increase 1.
- Expanding the provider network outside the US, where the company already works with partners in several countries, could open new markets 1.
- AI tools could reduce curation costs and widen the range of products offered to life science companies 1.
Threats
- Competitors with greater resources or superior technology could reduce market share and pressure prices 1.
- A cybersecurity incident could expose confidential data and seriously damage reputation and provider relationships 1.
- Loss of network providers or major customers could reduce the volume of available data and revenue 1.
Risks
- Going concernhigh
The auditor included a substantial doubt paragraph about the company's ability to continue as a going concern, which depends on generating cash flows and obtaining financing 1.
- Listing bid price curehigh
The Nasdaq minimum bid price notice requires a cure by October 2026, and failure to comply could lead to delisting 2.
- Revenue concentrationmedium
Revenue is very small and comes from few customers, so losing one important client could have a disproportionate effect 12.
- Data securitymedium
The company handles sensitive medical data, and a cyber attack or internal error could create legal liability and loss of client trust 1.
- Intellectual property protectionlow
The technological advantage depends on protecting patents and trade secrets, and the company acknowledges it cannot predict with certainty whether its rights will be enforced 1.
Investment thesis
What would need to be true (bull case)
- If regulators and the pharmaceutical industry continue to give more weight to clinical practice data, an extensive federated network could become a competitive advantage that is hard to match 1.
- Growth in data delivery revenue in 2025 shows that focusing the company on iRWD is already producing commercial results 1.
- A network of over two thousand sites and in-house clinical curation could become hard for new entrants to replicate, especially if quality standards tighten 1.
What would break the thesis
- Persistent losses, a very large accumulated deficit and the going concern warning show that the business has not yet proven financially sustainable 1.
- Revenue remains very small relative to costs, and dependence on further financing could lead to dilution of existing shareholders 12.
- The market is competitive, and competitors with greater resources could capture clients or develop superior technology that makes the company's offer less attractive 1.
What to watch
- Cure of the Nasdaq minimum bid price conditionOctober 2026
- Trend in quarterly iRWD revenue and new customer additionsQ3 2026
- Financing measures and any shareholder dilutionnext 10-K
- Status of the going concern assessment in the next annual reportnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
OneMedNet operates in imaging real world data (iRWD), starting from an initial medical image exchange product called BEAM. The company connects healthcare providers such as hospitals and imaging centers with pharmaceutical companies, AI developers and clinical research organizations, delivering de-identified, curated imaging data according to a case selection protocol agreed with the client 1. Data stays locally at providers until it is licensed for a specific study.
The value proposition rests on the fact that clinical images and the context of the patient record are hard to access and standardize. The company says it covers the whole value chain, from its federated provider network to in-house clinical curation and preparation of case report forms for possible regulatory submissions 1. It links this offer to the need to bring treatments to patients faster, given that drug development often takes many years.
On revenue structure, the company reports two streams: iRWD, sold on a fixed fee per data unit and recognized on delivery, and BEAM, a subscription recognized ratably, with the BEAM platform decommissioned in May 2025 2. In the first half of 2026 quarterly revenue came only from data deliveries, showing the focus on iRWD 2.
Segments
iRWD (imaging real world data)
The main segment, sold to pharmaceutical companies, medical device makers, clinical research organizations and AI developers. Revenue comes from delivering data units at the price set in the contract, and in 2025 growth in this stream drove almost all of the rise in total revenue 1.
Market context
The company describes the market for real world data used for clinical evidence as emerging, with growing demand from the pharmaceutical and AI industries. The US drug regulator has set guidelines for using these data in regulatory approvals, and the company notes that about 90% of healthcare data by size is associated with imaging, which outlines the potential market size 1.
Actual market growth depends on adoption of these data in studies and regulatory filings, and the company acknowledges the market is highly competitive and that competitors may have greater resources 1. If demand develops as the company describes, providers with federated imaging networks could gain relevance, but this remains to be seen.
Trends
- Adoption of real world data in regulationtailwind
US drug regulator guidelines allow data from routine clinical practice to support approvals, creating demand for curated and traceable data. If this practice expands, the company could benefit directly 1.
- Artificial intelligence in clinical data analysismixed
AI tools are used to standardize, check quality and index images, which could lower curation costs. At the same time, fast AI development brings competitors with superior technology, a risk the company itself notes 1.
- Financial pressure and listing statusheadwind
The company has reported losses every year since inception and a going concern warning. The Nasdaq minimum bid price notice opens a cure period to October 2026, adding pressure on financing 12.
- Data privacy and security requirementsmixed
Medical data must be de-identified and protected under US, EU and other rules where the company operates, raising compliance costs but also the entry barrier for competitors 1.
Competitive position
The company acknowledges that the real world data market is highly competitive and that current or future competitors may have greater resources, better access to customers and strategic partnerships. A competing technology with superior operational or price performance could affect sales and margins 1.
The company's stated advantage lies in its federated provider network, in-house clinical curation and combined expertise in compliance, security and radiology. The source documents do not name competitors, so a detailed competitive profile remains limited to the information available 1.
- Unnamed competitors in available sources
The company's documents describe generic competitors in the real world data market without naming them, with greater resources and the ability to develop superior technologies 1.
- Electronic health record and registry data sources
The company mentions traditional real world data sources such as electronic health records, claims and registries, which can compete with the imaging offer 1.
- Data aggregators and data platforms
Historically, pharmaceutical companies bought data from aggregators, sometimes without knowing its quality, so these are substitutes for the offer 1.
- Consultants and third-party analysis vendors
Companies outsource data preparation to consultants or third-party vendors, which can offer alternatives for analysis projects 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- CEO-ul OneMedNet, Aaron Green, a vândut acțiuni în valoare de 47.762 de dolari - https://www.goldring.ro/roSurge — Google News · 11 Oct 2026 · RO
The latest news item in our archive is from 11 Oct 2026; the newest SEC filing is from 14 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report14 Oct 2026Other events
- Current report29 Sept 2026Item 3.03 · Amendments to articles or bylaws · Financial statements and exhibits
- Current report23 Sept 2026Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Proxy statement19 Aug 2026
- Quarterly report14 Aug 2026
- Current report24 Jul 2026Item 5.08 · Other events
- Current report01 Jul 2026Material agreement · Financial statements and exhibits
- Quarterly report15 May 2026
- Current report20 Apr 2026Delisting notice
- Annual report30 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / OneMedNet Corporation · 30 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / OneMedNet Corporation · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / OneMedNet Corporation · 23 May 2024
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.